{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037038","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.649832+00:00","generated_at":"2026-06-22T04:47:37.537506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Heron Therapeutics Q3 net loss narrows to $41.9M; APONVIE approved, launch Q1 2023","bullets":["Net product sales $26.6M (+15% YoY); net loss $41.9M vs $52.4M YoY; oncology franchise sales $23.9M (+13%).","ZYNRELEF unit demand grew 18% QoQ; Q4 net sales expected to rise 30-40% QoQ.","APONVIE (aprepitant) FDA approved Sep 16; U.S. launch planned Q1 2023.","Completed $75M private placement to strengthen balance sheet; cash $121.7M.","Full-year 2022 oncology care franchise guidance reaffirmed at $93-95M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037038","json":"https://secwatch.observer/filing/0001564590-22-037038.json","markdown":"https://secwatch.observer/filing/0001564590-22-037038.md","text":"https://secwatch.observer/filing/0001564590-22-037038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/0001564590-22-037038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/hrtx-8k_20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:47:37.537506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b54ac1cc655a3659728b2e5f4ea9d3dc5e0b4d6","claim":"HERON THERAPEUTICS, INC. /DE/ reported three and nine months ended September 30, 2022 results: revenue $26.6 million and $77.6 million, net income $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share. Guidance reaffirmed.","evidence_excerpt":"franchises and extend our runway against a challenging external backdrop.” Financial Results Net product sales for the three and nine months ended September 30, 2022 were $26.6 million and $77.6 million, respectively, compared to $23.2 million and $65.7 million, respectively, for the same periods in 2021. Heron’s net loss for the three and nine months ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/0001564590-22-037038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$26.6 million and $77.6 million"},{"label":"Net income","value":"$41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}